文献速递浆细胞疾病淋巴瘤

NKG2D介导的CD4细胞毒性T细胞在多发性骨髓瘤中的细胞毒性作用

NKG2D-mediated cytotoxicity of CD4 cytotoxic T cells in multiple myeloma.
PubMed 文献 · Blood · 2025-01-01

研究对多发性骨髓瘤不同进展阶段患者骨髓分选的CD4+ T细胞进行单细胞RNA测序和T细胞受体测序,鉴定出显著增多且克隆扩增的CD4+细胞毒性T淋巴细胞(CTL)状态,其杀伤骨髓瘤细胞的能力可被NKG2D阻断所消除,且NKG2D+CD4+ CTL丰度与患者生存改善相关。

要点

  • 多发性骨髓瘤患者骨髓中CD4+ CTL显著增多并克隆扩增。
  • CD4+ CTL可直接杀伤骨髓瘤细胞,该细胞毒性可被NKG2D阻断消除。
  • NKG2D+CD4+ CTL丰度与多发性骨髓瘤患者生存改善相关。

核心结论

  • 研究提示利用CD4+ CTL可能为增强多发性骨髓瘤免疫治疗疗效提供新策略。

研究设计与样本

  • 对多发性骨髓瘤不同进展阶段患者骨髓分选的CD4+ T细胞进行单细胞RNA测序和T细胞受体测序。

主要发现

  • 鉴定出几种不同的CD4+细胞毒性T淋巴细胞状态,在多发性骨髓瘤患者中显著增多并克隆扩增。
  • CD4+ CTL显示提示细胞毒性的转录和表型特征,能直接杀伤骨髓瘤细胞。
  • NKG2D阻断可消除CD4+ CTL对骨髓瘤细胞的细胞毒性。
  • NKG2D+CD4+ CTL丰度与多发性骨髓瘤患者生存改善相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Emerging evidence indicates that CD4+ T cells contribute to antitumor immunity beyond their traditional roles as helpers or regulators. However, the specific subset of CD4+ T cells mediating beneficial outcomes in patients with multiple myeloma remains unclear. Here, we performed single-cell RNA sequencing and T-cell receptor sequencing on CD4+ T cells sorted from the bone marrow of patients across the stages of myeloma progression. We identified several distinct states of CD4+ cytotoxic T lymphocytes (CTLs) that were significantly increased and clonally expanded in patients with myeloma. CD4+ CTLs displayed transcriptional and phenotypic characteristics indicative of cytotoxicity, demonstrating their ability to directly kill myeloma cells. This cytotoxicity, however, was abrogated by NKG2D blockade. Notably, the abundance of NKG2D+CD4+ CTLs correlated with improved survival in patients with myeloma. Our findings suggest that harnessing CD4+ CTLs could lead to novel strategies for enhancing immunotherapy outcomes in multiple myeloma.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kim S, Kwak JE, Koh JY, et al. NKG2D-mediated cytotoxicity of CD4 cytotoxic T cells in multiple myeloma. Blood. 2025. PMID: 40106762. doi:10.1182/blood.2024025875

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。